Adjuvant Tamoxifen Reduces 15-Year Risk of Recurrence in ‘Good Risk’ DCIS Without Radiation Therapy
Adjuvant tamoxifen was associated with a reduced risk of 15-year ipsilateral breast cancer recurrence as well as invasive ipsilateral breast cancer recurrence...
Novel AI Platform May Help Identify Patients Likely to Benefit Most From Clinical Trials
Researchers have demonstrated that a novel artificial intelligence (AI)-based platform could aid physicians and patients in assessing the benefit...
Primary Lung Tumor SBRT Followed by Mediastinal Chemoradiotherapy in Locally Advanced NSCLC
In a phase II trial reported in The Lancet Oncology, Heinzerling et al found that primary lung tumor stereotactic body radiotherapy...
Adjuvant Dose-Dense vs Conventional Chemotherapy in Node-Positive Breast Cancer
As reported in the Journal of Clinical Oncology by Filho et al, 12-year follow-up of the CALBG (Alliance) C9741 trial has shown a sustained advantage...
Improvements in BRCA2 Testing Could Enhance Cancer Risk Assessment, Patient Care
Researchers may have advanced the understanding of genetic alterations in the BRCA2 gene, according to a recent study...
IDEA Awardees’ Reflections on the 2024 ASCO Annual Meeting
Ramy Sedhom and colleagues on Optimizing Cancer Care for Older Adults
Ilana Hellmann: Reflections on a Father’s Cancer Journey
Connor J. Kinslow and colleagues on Breast Implant–Related Cancers
Lorcan Ruane and colleagues on Cardiotoxicity: How Far Have We Come?
Sponsored Content
Sponsored by Lilly Medical Affairs
The Critical Role of Navigators in Improving Access to First-Line Precision Oncology Therapies for Advanced NSCLC
SPONSORED BY LILLY MEDICAL AFFAIRS
Navigating the Treatment Landscape for Double-Refractory CLL/SLLMore Top Stories
Some Patients With Low-Risk Ductal Carcinoma In Situ May Be Able to Avoid Surgery
Active monitoring appears to be a safe strategy for the management of some patients with low-risk ductal carcinoma in situ (DCIS), proving noninferior to guideline-concordant management of this patient population (ie, surgery with or without radiation therapy). After 2 years, the rate of invasive...
Addition of Cyclophosphamide to Posttransplantation GVHD Prophylaxis
As reported in the Journal of Clinical Oncology by Holtan et al, the addition of cyclophosphamide to posttransplantation graft-vs-host disease (GVHD) prophylaxis with tacrolimus and mycophenolate mofetil was associated with improved patient-reported outcomes in the phase III BMT CTN 1703 trial in...
AQUILA Trial: Daratumumab Proves Beneficial in Smoldering Multiple Myeloma
Patients with smoldering multiple myeloma derived a significant progression-free survival benefit, along with other positive outcomes, from 3 years of subcutaneous use of the monoclonal antibody daratumumab as compared with active monitoring in the phase III AQUILA study.1 These findings were...
Getting a Lung Cancer Diagnosis Was Shocking
For more than a year before my diagnosis of stage IA non–small cell lung cancer (NSCLC), in 2020, I had been self-treating a relentless chronic cough and a slight feeling of tightness in my chest. The symptoms were similar to asthma, so I began using albuterol inhalers. When they stopped working, I ...
Advanced NSCLC With Brain Metastases: Potential Novel Therapeutic Option
In a Chinese phase II study (C-Brain) reported in The Lancet Oncology, Xu et al found that brain radiotherapy in combination with camrelizumab and platinum-doublet chemotherapy produced “promising” results in patients with previously untreated advanced non–small cell lung cancer (NSCLC) with brain...
2.83% Medicare Physician Reimbursement Cut Finalized for 2025; Estimated 4% Cut for Medical Oncology
Late in 2024, the Centers for Medicare & Medicaid Services (CMS) issued the 2025 Physician Fee Schedule (PFS) final rule adopting changes for Medicare payments under the PFS. CMS also released the 2025 Hospital Outpatient Prospective Payment System final rule, which sets hospital outpatient...
Addition of Lenvatinib/Pembrolizumab to TACE in Unresectable Nonmetastatic HCC
As reported in The Lancet by Kudo et al, the phase III LEAP-012 trial has shown a significant progression-free survival benefit with the addition of lenvatinib and pembrolizumab to transarterial chemoembolization (TACE) in patients with unresectable nonmetastatic hepatocellular carcinoma (HCC). A...
